
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group is a strong player in the biologics industry, with a portfolio of successful amniograft products for the wound care and burn markets, as well as recent expansion into the surgical space. The company is well positioned to capitalize on the shift in settings of care and strong clinical data supporting its products. While recent reimbursement issues may have impacted the stock, its established track record and cost reduction initiatives make it a strong investment opportunity for long-term growth.
Bears say
MiMedx Group is struggling with sluggish recovery in the wound care market and the company is expected to incur a one-time restructuring charge in the second quarter of 2026. Additionally, there are risks related to tissue donorship and 361 regulated products, which could potentially impact the company's business. Furthermore, MDXG relies heavily on contracts with GPOs and IDNs, which could also pose a risk if terminated or not extended. While MDXG has a diverse portfolio of products and a strong track record, these risks and market challenges may hinder their future growth and financial performance.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares